AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01684917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metabolomic and Energy Intake Restriction
Description: Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
Study NCT01684917 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metabolomic and Energy Intake Restriction
Description: Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
Study NCT01684917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metabolomic and Energy Intake Restriction
Description: Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
Study NCT01001221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1
Study NCT02299154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological questionnaires
Description: Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
Study NCT02383056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilux
Description: Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
Study NCT02383056 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Omnilux Sham
Description: Sham light instead of phototherapy from the same light device
Study NCT01001221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1.
Study NCT04460885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
Study NCT04460885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
Study NCT04257357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-weeks supervised exercise program
Description: Please refer to group description
Study NCT00005829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00978796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
Study NCT04257357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Please refer to group description
Study NCT03566290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
Study NCT00978796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
Study NCT01813929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
Study NCT01813929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
Study NCT00007345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Study NCT05747053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AlloSure
Description: AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
Study NCT03724136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Bone Marrow Stem Cell (BMSC) Fraction
Description: 14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
Study NCT03724136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction
Description: Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
Study NCT03724136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near Infrared Light
Description: Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
Study NCT05747053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PAXGene
Description: 1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
Study NCT05249439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-SatPro weight loss programme
Description: I-SatPro weight loss programme: patients asked to make changes to food choices, the timing of eating, exercise, sleep, eating habits and behaviour changes related to self-care and wellbeing
Study NCT05249439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-SatPro weight loss programme
Description: I-SatPro weight loss programme: patients asked to make changes to food choices, the timing of eating, exercise, sleep, eating habits and behaviour changes related to self-care and wellbeing
Study NCT01776541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine
Study NCT01694173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell therapy- SPD artery
Description: A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
Study NCT01694173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy- splenic artery
Description: 7 patients will receive stem cells infusion through splenic artery.
Study NCT01694173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy-intravenous
Description: 7 patients will receive stem cells infusion through peripheral intravenous route.
Study NCT01694173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo -sham procedure
Description: 7 patients will receive infusion of normal saline and will act as control groups
Study NCT00618618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study NCT00618618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00087152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
Study NCT00087152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 400 mg by mouth daily
Study NCT05321901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial Exercise Therapy approach (BETY)
Description: The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
Study NCT05321901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
Study NCT04662021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
Study NCT01735422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hFSH
Description: Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
Study NCT01735422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hFSH
Description: Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
Study NCT01735422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hLH
Description: Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Study NCT04410523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment
Study NCT01735422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: u-hCG
Description: Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Study NCT04238910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximizing Energy
Description: The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.
Study NCT04238910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
Study NCT04592939 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate weight bearing after surgery
Description: immediate weight bearing
Study NCT04592939 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 6 weeks of toe-touch weight bearing after surgery
Description: 6 weeks of toe-touch weight bearing
Study NCT03199976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Tiotropium Bromide 2.5 µg/dose inhaled aerosol
Study NCT03199976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate 125 µg/dose inhaled aerosol
Study NCT03199976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol 0.1 mg/dose inhaled aerosol
Study NCT03199976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol 0.1 mg/dose inhaled aerosol
Study NCT03868514 — intervention group
Intervention type: DEVICE
Intervention: TiLOOP® Bra Pocket
Description: Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
Study NCT01561014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01561014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01561014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01561014 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT01561014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgical resection
Study NCT01561014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative study
Study NCT01561014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative study
Study NCT01561014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative study
Study NCT01561014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01561014 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative study
Study NCT01561014 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo F18 PET and CT scan
Study NCT01440959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
Study NCT03814811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Osteocalcin-positive (cOC) cells
Description: Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
Study NCT02476617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: ombitasvir/ABT-450/ritonavir tablets
Study NCT02476617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: dasabuvir tablets
Study NCT02476617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: ribavirin tablets
Study NCT02689440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02689440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02689440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04146597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
Study NCT01876836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: i-gel placed after induction
Study NCT01876836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-LMA
Description: placed after induction
Study NCT01495949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate
Description: During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
Study NCT01495949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiopentone
Description: During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
Study NCT00580619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Function Testing
Description: The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
Study NCT00580619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline infusions
Description: The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
Study NCT00580619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA trimethaphan
Description: Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
Study NCT00580619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyldopa
Description: Aldomet oral twice a day for 12 weeks
Study NCT00900653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynoflor E (low dose estriol with lactobacillus)
Description: The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
Study NCT01630148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin
Description: Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
Study NCT00325897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrolide Antibiotic (Azithromycin)
Description: Azithromycin (daily capsule, 250 mg for 12 months)
Study NCT00325897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken on a daily basis